ILDRU: Interstitial Lung Disease Research Unit Biobank

Sponsor

University of Kansas Medical Center (Other)

Overall Status

Recruiting

CT.gov ID

NCT05392881

Collaborator

(none)

1,000

Enrollment

Location

126.7

Anticipated Duration (Months)

7.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.

Condition or Disease	Intervention/Treatment	Phase
Interstitial Lung Disease Sarcoidosis Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Hypersensitivity Pneumonitis

Detailed Description

The University of Kansas ILD and Rare Lung Disease clinic sees hundreds of new patients per year. We would like to leverage this resource to develop an Interstitial Lung Disease Research Unit (ILDRU) repository and database to help develop new methods for early diagnosis, uncover underlying genetic and environmental risk factors, as well as potential treatment targets in the broad range of interstitial lung diseases and rare lung diseases (RLD).

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

1000 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

University of Kansas Medical Center Interstitial Lung Disease Research Unit (ILDRU) Biobank

Actual Study Start Date :

Aug 9, 2021

Anticipated Primary Completion Date :

Aug 1, 2031

Anticipated Study Completion Date :

Mar 1, 2032

Outcome Measures

Primary Outcome Measures

Collect clinically obtained data for patients with ILD, RLD and risk for ILD/RLD to support research. [Enrollment to Year 10]
Establish a collection of biological samples from patients with ILD, RLD and subjects at risk for ILD. [Enrollment to Year 10]
Correlate biological samples with individual longitudinal clinical data. [Enrollment to Year 10]
Provide biological samples to researchers performing studies in ILD and RLD. [Enrollment to Year 10]
Collect historical data and imaging from deceased patients with ILD. [Enrollment to Year 10]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)
The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS.
The participant is ≥ 18 years of age.
The participant has signed an approved consent for this study (living patients only)